To a greater extent, approximately 40%–60% of melanoma patients have BRAF mutations [6], and amongst these patients, 80%–90% exhibit a substitution of valine with glutamic acid at codon 600 (BRAFV600E) [6–8]. This evidence concerns the gene BRAF and melanoma.